^
Association details:
| Biomarker: | EGFR exon 21 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Vizimpro (dacomitinib) (pan-HER inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Initial low dose of dacomitinib for first-line treatment of patients with EGFR exon 21 mutated non-small cell lung cancer.
Published date:
05/19/2021
Excerpt:
Among the 9 patients with EGFR exon 21 mutated NSCLC in this study, 8 patients harboring L858R mutation...They all received low dose of dacomitinib as initial treatment. The ORR was 77.8% and DCR was 100%....Our study showed that dacomitinib (15 mg, once a day) may be also effective for patients harboring EGFR exon 21 mutated NSCLC...
DOI:
10.1200/JCO.2021.39.15_suppl.e21083
